Treatment with transthyretin-lowering RNA interference therapeutics is not associated with ocular or other clinical events due to vitamin A reduction: pooled analysis of vutrisiran and patisiran data

Onpattro (patisiran) - Alnylam, Sanofi

Amvuttra (vutrisiran) - Alnylam

https://esc365.escardio.org/Heart-Failure/Sessions/18914

W Blaner1; C Whelan2; J Gonzalez-Costello3; J Wixner4; M S Maurer5; J S Pulido6; Y Sekijima7; J L Berk8; L Obici9; W Zhao10; A Chan-Daniels10; L A Bilello10; KH V Lau10; T H Brannagan11

Feb 25, 2026